- Home
- VCEL vs NAMS Comparison
VCEL vs NAMS Comparison
Compare VCEL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- NAMS
- Stock Information
- Founded
- VCEL 1989
- NAMS 2019
- Country
- VCEL United States
- NAMS Netherlands
- Employees
- VCEL N/A
- NAMS N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- NAMS Health Care
- Exchange
- VCEL Nasdaq
- NAMS Nasdaq
- Market Cap
- VCEL 2.8B
- NAMS 2.7B
- IPO Year
- VCEL 1997
- NAMS N/A
- Fundamental
- Price
- VCEL $59.07
- NAMS $23.55
- Analyst Decision
- VCEL Strong Buy
- NAMS Strong Buy
- Analyst Count
- VCEL 7
- NAMS 7
- Target Price
- VCEL $62.29
- NAMS $38.17
- AVG Volume (30 Days)
- VCEL 424.2K
- NAMS 581.4K
- Earning Date
- VCEL 02-27-2025
- NAMS 02-06-2025
- Dividend Yield
- VCEL N/A
- NAMS N/A
- EPS Growth
- VCEL N/A
- NAMS N/A
- EPS
- VCEL 0.07
- NAMS N/A
- Revenue
- VCEL $226,844,000.00
- NAMS $33,594,000.00
- Revenue This Year
- VCEL $23.82
- NAMS $131.53
- Revenue Next Year
- VCEL $22.51
- NAMS N/A
- P/E Ratio
- VCEL $821.76
- NAMS N/A
- Revenue Growth
- VCEL 22.48
- NAMS 78.77
- 52 Week Low
- VCEL $38.69
- NAMS $15.19
- 52 Week High
- VCEL $61.49
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- VCEL 57.96
- NAMS 44.17
- Support Level
- VCEL $53.00
- NAMS $22.53
- Resistance Level
- VCEL $60.93
- NAMS $26.71
- Average True Range (ATR)
- VCEL 2.60
- NAMS 0.97
- MACD
- VCEL -0.06
- NAMS -0.45
- Stochastic Oscillator
- VCEL 76.54
- NAMS 23.89
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.